Neue Paradigmen in der Klassifikation und Behandlung des Typ-2-Diabetes

• Literatur

• 1 Polonsky KS. The Past 200 Years in Diabetes. New England Journal of Medicine 2012; 367: 1332-1340
• 2 Tamayo T, Brinks R, Hoyer A. et al. The Prevalence and Incidence of Diabetes in Germany. Dtsch Arztebl Int 2016; 113: 177-182
• 3 Newman B, Selby JV, King MC. et al. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 1987; 30: 763-768
• 4 Mahajan A, Wessel J, Willems SM. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nature Genetics 2018; 50: 559
• 5 Schäfer SA, Tschritter O, Machicao F. et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50: 2443-2450
• 6 Wagner R, Staiger H, Ullrich S. et al. Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1. Mol Metab 2014; 3: 261-267
• 7 Wagner R, Tabák ÁG, Fehlert E. et al. Excessive fuel availability amplifies the FTO-mediated obesity risk: results from the TUEF and Whitehall II studies. Scientific Reports 2017; 7: 15486
• 8 Jaghutriz BA, Heni M, Lutz SZ. et al. Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion. Front Endocrinol (Lausanne) 2019; 10: 72
• 9 Groop L, Pociot F. Genetics of diabetes – Are we missing the genes or the disease?. Mol Cell Endocrinol 2014; 382: 726-739
• 10 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
• 11 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
• 12 Wagner R, Fritsche A. Pathologisch-genetisch orientierte Diabetes-Reklassifizierung. Dtsch med Wochenschr 2020; 145: 601-608
• 13 Misra S, Wagner R, Ozkan B. et al. Precision subclassification of type 2 diabetes: a systematic review. Commun Med (Lond) 2023; 3: 138
• 14 Wagner R. Type 2 diabetes: Is categorisation into subgroups an advantage?. MMW Fortschr Med 2024; 166: 68-71
• 15 Nair ATN, Wesolowska-Andersen A, Brorsson C. et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med 2022; 28: 982-988
• 16 Schön M, Prystupa K, Mori T. et al. Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort. The Lancet Diabetes & Endocrinology 2024; 12: 119-131
• 17 Häring H-U. Novel phenotypes of prediabetes?. Diabetologia 2016; 59: 1806-1818
• 18 Wagner R, Heni M, Tabák AG. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 2021; 27: 49-57
• 19 Wagner R, Eckstein SS, Yamazaki H. et al. Metabolic implications of pancreatic fat accumulation. Nat Rev Endocrinol 2021; 1-12
• 20 Wagner R, Machann J, Lehmann R. et al. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia 2012; 55: 2054-2058
• 21 Yamazaki H, Tauchi S, Machann J. et al. Fat Distribution Patterns and Future Type 2 Diabetes. Diabetes 2022; 71: 1937-1945
• 22 Wagner R, Jaghutriz BA, Gerst F. et al. Pancreatic steatosis associates with impaired insulin secretion in genetically predisposed individuals. J Clin Endocrinol Metab 2020; 105: 3518-3525
• 23 Wagner R, Machann J, Guthoff M. et al. The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Sci Rep 2017; 7: 2261
• 24 Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122: 4-12
• 25 Wagner R, Hakaste LH, Ahlqvist E. et al. Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance. Diabetes 2017; 66: 1373-1379
• 26 Guzman CB, Zhang XM, Liu R. et al. Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes. Diabetes Obes Metab 2017; 19: 1521-1528
• 27 Sanyal AJ, Bedossa P, Fraessdorf M. et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 2024; 391: 311-319